3--3-methyl-butan | 90795-22-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3--3-methyl-butan
• 英文别名: Methyl-isopropyl-t-amyl-amin；3--3-methyl-butan；NoName_3285；N,2-dimethyl-N-propan-2-ylbutan-2-amine
• CAS: 90795-22-5
• 化学式: C₉H₂₁N
• 分子量: 143.272
• InChiKey: HJYWUJDNOLNXCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-Isopropylamino-3-methyl-1-butin 在 镍 氢气 、 potassium carbonate 作用下， 生成 3--3-methyl-butan
  参考文献：
  名称：

  Highly Hindered Aliphatic Tertiary Amines

  摘要：

  DOI：

  10.1021/jo01068a036

文献信息

• NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS
  申请人：Galapagos NV

  公开号：US20170362227A1

  公开（公告）日：2017-12-21

  The present invention discloses compounds according to Formula I: Wherein R 1a , R 1b , R 2 , R 4 , R 5 , R 6a , R 6b , R 7 , R 8 , W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

  本发明揭示了符合公式I的化合物：其中，R1a，R1b，R2，R4，R5，R6a，R6b，R7，R8，W，X，Cy和下标a如本文所定义。本发明涉及抑制自体脂肪酸酰肌醇磷酸酯酶（NPP2或ENPP2）的化合物，其制备方法，包含它们的制药组合物和使用它们的治疗方法，用于预防和/或治疗涉及纤维化疾病，增生性疾病，炎症性疾病，自身免疫性疾病，呼吸系统疾病，心血管疾病，神经退行性疾病，皮肤疾病和/或异常血管生成相关疾病，通过给予本发明的化合物。
• AZO-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS
  申请人：Kwong Cecil D.

  公开号：US20110286964A1

  公开（公告）日：2011-11-24

  The present invention provides compounds of Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R 1 , X, Y, Z, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 18 , R 19 , and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing dieases or disorders such as viral infections and virus-related disorders.

  本发明提供了式(I)的化合物：（将在论文中以纸质形式出现的化学式插入此处）（I）及其互变异构体、异构体和酯类，以及所述化合物的药学上可接受的盐、溶剂化物和前药，其中每个R、R1、X、Y、Z、R2、R3、R4、R5、R6、R7、R8、R9、R18、R19和n均是独立选择并如所定义。还提供了包含此类化合物的组合物。本发明的化合物是HCV抑制剂，可用于治疗或预防病毒感染和与病毒相关的疾病或障碍，单独或与其他治疗剂一起使用。
• Compounds which selectively modulate the CB2 receptor
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2716635B1

  公开（公告）日：2017-02-01
• ETHENYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS
  申请人：Kwong Cecil D.

  公开号：US20110286965A1

  公开（公告）日：2011-11-24

  The present invention provides compounds of Formula (A): (Chemical formula should be inserted here as it appears on abstract in paper form) (A) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein wherein each of R, R 1 , X, Y, Z, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 18 , R 19 , R 22 , R 23 , and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.
• SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS
  申请人：Arasappan Ashok

  公开号：US20110318305A1

  公开（公告）日：2011-12-29

  The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R 1 , X, Y, Z, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 18 , R 19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.